Erez Israeli, CEO of Dr. Reddy's, discusses the potential impact of Trump's proposed drug pricing changes, noting that ...

Shares of Dr. Reddy’s Laboratories are on track to break through a critical range between ₹1,200 and ₹1,220 where surpassing ...

Brokerages' mixed review on Dr Reddy's higher than estimated earnings performance; cautiousness suggests recalibration of ...

Dr Reddy dreamt of providing a world-class medical facility in India so that Indians didn’t need to travel abroad for ...

The sharp 250 basis points quarter-on-quarter decline in gross margin (the third consecutive sequential fall) reinforces ...

Dr Reddy's, Navin Fluorine, Birla Corporation, Triveni Turbines, Shakti Pumps, Electrosteel Castings, Apollo Pipes. These ...

Dr. Reddy's Laboratories Ltd. closed 19.12% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Dr. Reddy's Laboratories Ltd. closed 18.57% short of its 52-week high of 1,420.20 rupees, which the company achieved on ...

Dr. Reddy's Laboratories added 3.34% to Rs 1,193.75 after the company reported a consolidated net profit of Rs 1,594 crore for the quarter ended March 2025 (Q4FY25), marking a 22% year-on-year ...

Markets top brokerage firms forecast suggest that Dr Reddys Laboratories will report a net profit of approximately Rs 1,456.5 ...

Net Sales at Rs 8,528.40 crore in March 2025 up 19.89% from Rs. 7,113.80 crore in March 2024. Quarterly Net Profit at Rs.

Dr. Reddys Laboratories reported a 22% YoY rise in Q4 net profit to Rs 1,594 crore, exceeding estimates. Revenue grew 20% to ...